These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 8301302)

  • 1. Immunotherapy for multiple sclerosis.
    Hughes RA
    J Neurol Neurosurg Psychiatry; 1994 Jan; 57(1):3-6. PubMed ID: 8301302
    [No Abstract]   [Full Text] [Related]  

  • 2. Current disease-modifying therapies in multiple sclerosis.
    Kieseier BC; Hartung HP
    Semin Neurol; 2003 Jun; 23(2):133-46. PubMed ID: 12894379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New treatments and azathioprine in multiple sclerosis.
    Kolar OJ
    Lancet; 1997 Oct; 350(9083):1033. PubMed ID: 9329539
    [No Abstract]   [Full Text] [Related]  

  • 4. Multiple sclerosis.
    Ford H; Nicholas R
    Clin Evid; 2005 Dec; (14):1637-51. PubMed ID: 16620466
    [No Abstract]   [Full Text] [Related]  

  • 5. Multiple sclerosis.
    Boggild M; Ford H
    Clin Evid; 2003 Jun; (9):1459-73. PubMed ID: 15366193
    [No Abstract]   [Full Text] [Related]  

  • 6. Effects of interferon beta, cyclophosphamide and azathioprine on cytokine profile in patients with multiple sclerosis.
    Totaro R; Passacantando A; Russo T; Parzanese I; Rascente M; Marini C; Tonietti G; Carolei A
    Int J Immunopathol Pharmacol; 2005; 18(2):377-83. PubMed ID: 15888259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy in multiple sclerosis, Part 2.
    Becker CC; Gidal BE; Fleming JO
    Am J Health Syst Pharm; 1995 Oct; 52(19):2105-20; quiz 2132-4. PubMed ID: 8535945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interferon, azathioprine and corticosteroids in multiple sclerosis: 6-year follow-up of the ASA cohort.
    Kalincik T; Horakova D; Dolezal O; Krasensky J; Vaneckova M; Seidl Z; Havrdova E
    Clin Neurol Neurosurg; 2012 Sep; 114(7):940-6. PubMed ID: 22402204
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disease-modifying drugs for multiple sclerosis: a rapid and systematic review.
    Clegg A; Bryant J; Milne R
    Health Technol Assess; 2000; 4(9):i-iv, 1-101. PubMed ID: 10944743
    [No Abstract]   [Full Text] [Related]  

  • 10. Acute multiple sclerosis characterized by extensive mononuclear phagocyte infiltration.
    Shields DC; Avgeropoulos NG; Banik NL; Tyor WR
    Neurochem Res; 2000 Nov; 25(11):1517-20. PubMed ID: 11071372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Designing rational therapies for multiple sclerosis.
    Steinman L; Conlon P
    Biotechnology (N Y); 1995 Feb; 13(2):118-20. PubMed ID: 9678929
    [No Abstract]   [Full Text] [Related]  

  • 12. Immunopathogenesis and immunotherapeutic approaches in multiple sclerosis.
    Lim ET; Giovannoni G
    Expert Rev Neurother; 2005 May; 5(3):379-90. PubMed ID: 15938671
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disease-modifying drugs for the early treatment of multiple sclerosis.
    Flachenecker P
    Expert Rev Neurother; 2004 May; 4(3):455-63. PubMed ID: 15853542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical practice of immunosuppressive treatments in multiple sclerosis: results of a second international questionnaire.
    Hommes OR; Weiner HL
    J Neurol Sci; 2004 Aug; 223(1):65-7. PubMed ID: 15261563
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Cytostatic drugs in the treatment of rheumatic and connective tissue diseases].
    Martio J
    Duodecim; 1998; 114(3):243-51. PubMed ID: 10895494
    [No Abstract]   [Full Text] [Related]  

  • 16. A double blind, placebo-controlled, phase II, add-on study of cyclophosphamide (CTX) for 24 months in patients affected by multiple sclerosis on a background therapy with interferon-beta study denomination: CYCLIN.
    Patti F; Amato MP; Filippi M; Gallo P; Trojano M; Comi GC
    J Neurol Sci; 2004 Aug; 223(1):69-71. PubMed ID: 15261564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Multiple sclerosis--current status of therapy].
    Reichel D; Kölmel HW
    Z Arztl Fortbild (Jena); 1995 May; 89(2):151-8. PubMed ID: 7610682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [New treatments for multiple sclerosis].
    Masdeu JC
    Rev Neurol; 1996 Jun; 24(130):708-11. PubMed ID: 8653621
    [No Abstract]   [Full Text] [Related]  

  • 19. The treatment of multiple sclerosis.
    Kott HS
    Med Clin North Am; 1972 May; 56(3):711-6. PubMed ID: 4338391
    [No Abstract]   [Full Text] [Related]  

  • 20. Immunotherapy of multiple sclerosis: where are we? Where should we go?
    Martin R; Stürzebecher CS; McFarland HF
    Nat Immunol; 2001 Sep; 2(9):785-8. PubMed ID: 11526386
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.